Catheter Precision Inc.
$ 1.61
0.62%
24 Feb - close price
- Market Cap 3,053,400 USD
- Current Price $ 1.61
- High / Low $ 1.63 / 1.55
- Stock P/E 0.06
- Book Value 6.84
- EPS 33.63
- Next Earning Report 2026-03-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -1.84 %
- 52 Week High 15.77
- 52 Week Low 1.14
About
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-11 | 2025-05-05 | 2025-03-27 | 2024-11-14 | 2024-08-14 | 2024-05-06 | 2024-03-29 | 2023-12-21 | 2023-08-14 | 2023-06-02 | 2023-03-14 |
| Reported EPS | -1.7 | -5.93 | -0.3585 | -1.3475 | -38.19 | -105.83 | -68.4 | -2.8 | -0.28 | -11.5 | -24.65 | -3.83 |
| Estimated EPS | 0.08 | 0.02 | 0.05 | -0.2 | -3.42 | -4.94 | -7.98 | -2.3 | -0.23 | -3.02 | -0.34 | -8 |
| Surprise | -1.78 | -5.95 | -0.4085 | -1.1475 | -34.77 | -100.89 | -60.42 | -0.5 | -0.05 | -8.48 | -24.31 | 4.17 |
| Surprise Percentage | -2225% | -29750% | -817% | -573.75% | -1016.6667% | -2042.3077% | -757.1429% | -21.7391% | -21.7391% | -280.7947% | -7150% | 52.125% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTAK
2026-02-19 12:57:36
Catheter Precision (NYSE American: VTAK) has announced the strategic divestment of its non-core atherectomy catheter technologies to strengthen its balance sheet and focus on high-growth electrophysiology. The deal includes an upfront cash payment, a 5% equity stake in the acquiring company with anti-dilution protection, and a ten-year royalty agreement on net sales. This move aims to enhance capital efficiency and accelerate execution of its core cardiac arrhythmia solutions.
2026-02-19 12:57:36
Catheter Precision (VTAK) has announced the sale of its atherectomy catheter technologies, including FDA approvals and patents, to a strategic acquirer. The deal includes an upfront cash payment of $15,000, a 5% equity stake in the buyer with anti-dilution protection, and a 10-year royalty agreement starting at 1.5% and increasing to 3% on quarterly net sales above $5 million. This divestiture aims to strengthen the company's balance sheet and sharpen its focus on its high-growth electrophysiology platform.
2026-02-17 20:28:18
Catheter Precision, Inc. has acquired a 20% equity interest in Fly Flyte, Inc., a subsidiary of Creatd, Inc., through a secondary purchase. Fly Flyte specializes in AI-enabled regional aviation services, aligning with Creatd's strategy to develop technology-driven subsidiaries. Despite Creatd's stock decline and "WEAK" financial health, the company continues to pursue acquisitions to build its portfolio of operating companies.
2026-02-17 17:28:22
Catheter Precision, Inc. (VTAK) has announced a strategic minority investment, acquiring a 19.98% equity stake in Fly Flyte, Inc., an FAA-certified regional aviation operator that utilizes AI-enabled operations and a fleet of Cirrus Vision Jets. This investment provides VTAK immediate exposure to a revenue-generating aviation business with scalable fleet expansion capabilities and technology-driven operating optimization. Flyte operates today in short-haul regional markets, generating revenue and operating data, while strategically positioning itself for the future commercialization of eVTOL technology.
2026-02-17 12:28:22
Catheter Precision (VTAK) has acquired a 19.98% strategic minority stake in Fly Flyte, Inc., an FAA-certified regional aviation operator that leverages AI-enabled operations and a fleet of Cirrus Vision Jets for short-haul flights. This investment provides VTAK immediate exposure to a revenue-generating business in the rapidly evolving air mobility sector, aiming for scalable fleet expansion and future monetization opportunities. The move diversifies VTAK's capital allocation and strategically positions it in regional air mobility ahead of potential eVTOL commercialization.
2026-02-13 09:27:58
Catheter Precision, Inc. has secured up to $36.5 million in strategic institutional financing, terminating its previous at-the-market equity offering program. This financing aims to strengthen the company's balance sheet, convert short-term liabilities to long-term, and fund accelerated growth initiatives for its advanced electrophysiology solutions. The move reflects increased institutional investor confidence and positions the company for disciplined expansion.
